We have changed our visitation policy for the safety of our patients and staff. Click here for the updated visitation policy and click here for information about COVID-19.

[LCID Study Number: 2017-084CIRB]

S1501 Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer Phase III [LCID Study Number: 2017-084]

The purpose of this study is to test whether carvedilol (a heart drug) can reduce the occurrence of heart problems during your cancer treatment for metastatic breast cancer. Carvedilol is FDA approved to treat congestive heart failure and high blood pressure.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-2734